Philips companions with Nuvo Group for distant being pregnant monitoring and extra digital well being briefs

Med tech large Royal Philips is partnering with Nuvo Group to help distant being pregnant monitoring in rural areas.

The collaboration will begin with a pilot program in rural Colorado utilizing Nuvo’s INVU distant monitoring system, which was cleared by the FDA last year. The businesses say this system might enhance entry to maternity care in rural communities, the place a lack of options contributes to worse outcomes and better mortality charges. 

“Digital options and ecosystem-building are essential enablers to addressing disparities in healthcare reminiscent of entry to maternal well being care in rural settings,” Sandra Lesenfants, basic supervisor, hospital affected person monitoring, at Philips, stated in an announcement. “With this collaboration, we’re extending the sight and attain of being pregnant care and bringing extra distant monitoring choices to the communities and expectant moms the place and after they want them most.”

Prescription digital therapeutics firm Pear Therapeutics will now be accessible in Epic’s App Orchard Gallery, permitting suppliers to observe sufferers utilizing the corporate’s therapeutics throughout the EHR.

Together with the PearConnect service platform within the gallery will enhance workflows for suppliers as they handle sufferers utilizing reSET or reSET-O for substance use and opioid use issues, the corporate stated. They’re going to be capable of assessment affected person progress and doc distant monitoring work for reimbursement.

“We’re excited to deliver this chance to develop entry to our PDTs, with the preliminary itemizing of our PearConnect platform within the App Orchard gallery to help reSET and reSET-O sufferers. We imagine Pear’s integration with Epic will create a pathway for healthcare suppliers to simply entry our PearConnect platform and allow scale to serve many extra sufferers,” Pear chief industrial officer Julia Strandberg stated in an announcement.

Digital actuality therapeutics startup AppliedVR introduced it has modified the title of its EaseVRx therapeutic to RelieVRx.

The system received FDA De Novo clearance to deal with power decrease again ache in November. AppliedVR plans to launch the rebranded RelieVRx in just a few markets this 12 months to arrange for its full launch in 2023. 

“Whereas ease of use is unquestionably an vital a part of our design, in the end we wished a reputation that higher mirrored how our modern product intends to supply life-changing aid. With demonstrated efficacy knowledge, ‘RelieVRx’ higher captures the core good thing about ache aid that the healthcare business is in search of: a prescription therapy choice that gives a singular modality whereas addressing unmet affected person wants,” cofounder and CEO Matthew Stoudt stated in an announcement. 

The corporate additionally introduced it had appointed Dr. Charisse Y. Sparks as chief medical officer to help the RelieVRx launch and its potential growth for different scientific wants. Sparks most lately labored at DePuySynthes, the orthopedic system arm of Johnson & Johnson.

“Racial, ethnic and financial disparities in power ache administration are effectively established. Dependable research present that these disparities present up within the undertreatment of ache in addition to overdose deaths, which proceed to extend,” Sparks stated in an announcement. “I’m wanting ahead to creating immersive therapeutics a normal of care in power ache administration and establishing AppliedVR as a pacesetter in well being fairness for the digital well being business.”


Leave a Reply